中国批准无毒品过敏阻塞器Bentrio nasal喷雾剂在中国大陆销售。 China approves Bentrio nasal spray, a drug-free allergy blocker, for sale in mainland China.

Altamira治疗术公司宣布其子公司Altamira Medica已经获得中国NMPA对Bentrio nasal喷雾的核准,该喷雾是一种无毒品的场外产品,旨在阻断空气中的过敏基因和经批准的病毒。 Altamira Therapeutics announced that its subsidiary Altamira Medica has received approval from China’s NMPA for Bentrio nasal spray, a drug-free, over-the-counter product designed to block airborne allergens and, where approved, viruses. 这项批准允许Nuance Pharma在中国大陆各地分发本特里奥,那里有近2亿人患有过敏脑膜炎。 The approval allows Nuance Pharma to distribute Bentrio across Mainland China, where nearly 200 million people suffer from allergic rhinitis. Bentrio在鼻子中形成保护凝胶层,以减少过敏接触。 Bentrio forms a protective gel layer in the nose to reduce allergen exposure. 临床试验,包括一项100名病人的研究,表明其症状大为减少,生活质量得到改善,而且安全性良好,与盐碱喷雾物相当。 Clinical trials, including a 100-patient study, showed it significantly reduced symptoms, improved quality of life, and was well-tolerated with safety comparable to saline sprays. 该产品无防腐剂,不含药品成分。 The product is preservative-free and does not contain pharmaceutical ingredients. 批准标志着在扩大中国大型消费卫生市场获得过敏救济的机会方面的一个重要里程碑。 The approval marks a major milestone in expanding access to allergy relief in China’s large consumer health market.